Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.

Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A.

Mol Pharmacol. 2019 Oct;96(4):419-429. doi: 10.1124/mol.119.116855.

PMID:
31467029
2.

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.

Haque M, Li J, Huang YH, Almowaled M, Barger CJ, Karpf AR, Wang P, Chen W, Turner SD, Lai R.

Cancers (Basel). 2019 Aug 6;11(8). pii: E1119. doi: 10.3390/cancers11081119.

3.

BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.

Hillman JC, Pugacheva EM, Barger CJ, Sribenja S, Rosario S, Albahrani M, Truskinovsky AM, Stablewski A, Liu S, Loukinov DI, Zentner GE, Lobanenkov VV, Karpf AR, Higgins MJ.

Mol Cancer Res. 2019 Oct;17(10):2051-2062. doi: 10.1158/1541-7786.MCR-19-0310. Epub 2019 Jul 10.

PMID:
31292201
4.

Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer.

Barger CJ, Branick C, Chee L, Karpf AR.

Cancers (Basel). 2019 Feb 21;11(2). pii: E251. doi: 10.3390/cancers11020251.

5.

Expression of the POTE gene family in human ovarian cancer.

Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR.

Sci Rep. 2018 Nov 20;8(1):17136. doi: 10.1038/s41598-018-35567-1.

6.

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.

Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, Brattain MG, Natarajan A.

Oncotarget. 2017 Dec 28;9(4):5216-5232. doi: 10.18632/oncotarget.23749. eCollection 2018 Jan 12.

7.

PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR.

Oncotarget. 2016 Jul 19;7(29):45352-45369. doi: 10.18632/oncotarget.9977.

8.

Protein Kinase Cα (PKCα) Is Resistant to Long Term Desensitization/Down-regulation by Prolonged Diacylglycerol Stimulation.

Lum MA, Barger CJ, Hsu AH, Leontieva OV, Black AR, Black JD.

J Biol Chem. 2016 Mar 18;291(12):6331-46. doi: 10.1074/jbc.M115.696211. Epub 2016 Jan 14.

9.

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.

Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.

Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.

10.

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.

Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR.

Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.

Supplemental Content

Loading ...
Support Center